Developing radioimmunotherapy of osteosarcoma using comparative oncology approach

使用比较肿瘤学方法开发骨肉瘤的放射免疫疗法

• 批准号: 389648
• 负责人: Dadachova Ekaterina
• 金额: $ 55.73万
• 依托单位: University of Saskatchewan
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2018
• 资助国家: 加拿大
• 起止时间: 2018-09-01 至 2023-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=389648&lang=en
• 关键词: 177lutetium; Companion Dogs With Osterosarcoma; Human Antibodies; Immunohistochemistry; Insulin Growth Factor Type 2 Receptor; Mouse Models; Non-Invasive Pet And Spect/Ct Imaging; Ostersarcoma; Radioimmunotherapy; Safety Studies

Osteosarcoma (OS) is the most common primary malignant bone tumor and the fifth most common primary malignancy among adolescents and young adults. Unfortunately, overall survival is approximately 70%, with no meaningful improvement realized in over 20 ye

骨肉瘤（OS）是最常见的原发性恶性骨肿瘤，在青少年和年轻人中排名第五。 不幸的是，总生存率约为70%，在20年以上的时间里没有实现有意义的改善。